JP2023102787A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023102787A5 JP2023102787A5 JP2023075517A JP2023075517A JP2023102787A5 JP 2023102787 A5 JP2023102787 A5 JP 2023102787A5 JP 2023075517 A JP2023075517 A JP 2023075517A JP 2023075517 A JP2023075517 A JP 2023075517A JP 2023102787 A5 JP2023102787 A5 JP 2023102787A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- docetaxel
- pharmaceutical composition
- tumor
- long
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 8
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 6
- 229960003668 docetaxel Drugs 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 230000036470 plasma concentration Effects 0.000 claims 4
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 3
- 230000007774 longterm Effects 0.000 claims 3
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 3
- 229960000311 ritonavir Drugs 0.000 claims 3
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000000955 neuroendocrine Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025049089A JP2025094189A (ja) | 2018-12-21 | 2025-03-24 | 癌の治療におけるドセタキセルの長期使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18215472.4 | 2018-12-21 | ||
| EP18215472 | 2018-12-21 | ||
| JP2021536409A JP2022515249A (ja) | 2018-12-21 | 2019-12-18 | 癌の治療におけるドセタキセルの長期使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536409A Division JP2022515249A (ja) | 2018-12-21 | 2019-12-18 | 癌の治療におけるドセタキセルの長期使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025049089A Division JP2025094189A (ja) | 2018-12-21 | 2025-03-24 | 癌の治療におけるドセタキセルの長期使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023102787A JP2023102787A (ja) | 2023-07-25 |
| JP2023102787A5 true JP2023102787A5 (enExample) | 2023-10-31 |
Family
ID=64901394
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536409A Pending JP2022515249A (ja) | 2018-12-21 | 2019-12-18 | 癌の治療におけるドセタキセルの長期使用 |
| JP2023075517A Pending JP2023102787A (ja) | 2018-12-21 | 2023-05-01 | 癌の治療におけるドセタキセルの長期使用 |
| JP2025049089A Pending JP2025094189A (ja) | 2018-12-21 | 2025-03-24 | 癌の治療におけるドセタキセルの長期使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536409A Pending JP2022515249A (ja) | 2018-12-21 | 2019-12-18 | 癌の治療におけるドセタキセルの長期使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025049089A Pending JP2025094189A (ja) | 2018-12-21 | 2025-03-24 | 癌の治療におけるドセタキセルの長期使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20220079910A1 (enExample) |
| EP (1) | EP3897610B1 (enExample) |
| JP (3) | JP2022515249A (enExample) |
| KR (1) | KR20220002860A (enExample) |
| CN (1) | CN113543781A (enExample) |
| AU (2) | AU2019410060A1 (enExample) |
| BR (1) | BR112021012255A2 (enExample) |
| CA (1) | CA3124316C (enExample) |
| CL (1) | CL2021001638A1 (enExample) |
| ES (1) | ES3026709T3 (enExample) |
| IL (1) | IL284213A (enExample) |
| MX (2) | MX2021007478A (enExample) |
| PE (1) | PE20220250A1 (enExample) |
| WO (1) | WO2020127606A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3124319C (en) * | 2018-12-21 | 2023-07-04 | Modra Pharmaceuticals B.V. | Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor |
| PE20220250A1 (es) * | 2018-12-21 | 2022-02-16 | Modra Pharmaceuticals B V | Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma |
| GB202201935D0 (en) | 2022-02-14 | 2022-03-30 | Modra Pharmaceuticals B V | Methods and compositions for treating cancer in taxane-resistant patients |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR054215A1 (es) | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
| US9089544B2 (en) * | 2007-08-24 | 2015-07-28 | Slotervaart Participaties Bv | Composition |
| GB0716591D0 (en) * | 2007-08-24 | 2007-10-03 | Vereniging Het Nl Kanker I | Composition |
| AU2008291930B2 (en) | 2007-08-24 | 2014-04-17 | Slotervaart Participaties Bv | Compositions for the treatment of neoplastic diseases |
| EP2328555A2 (en) | 2008-08-22 | 2011-06-08 | Slotervaart Participaties BV | Compositions for the treatment of neoplastic diseases |
| CA3124319C (en) * | 2018-12-21 | 2023-07-04 | Modra Pharmaceuticals B.V. | Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor |
| PE20220250A1 (es) * | 2018-12-21 | 2022-02-16 | Modra Pharmaceuticals B V | Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma |
-
2019
- 2019-12-18 PE PE2021001049A patent/PE20220250A1/es unknown
- 2019-12-18 KR KR1020217022968A patent/KR20220002860A/ko not_active Ceased
- 2019-12-18 BR BR112021012255-9A patent/BR112021012255A2/pt not_active Application Discontinuation
- 2019-12-18 MX MX2021007478A patent/MX2021007478A/es unknown
- 2019-12-18 CN CN201980090615.9A patent/CN113543781A/zh active Pending
- 2019-12-18 US US17/416,977 patent/US20220079910A1/en not_active Abandoned
- 2019-12-18 JP JP2021536409A patent/JP2022515249A/ja active Pending
- 2019-12-18 CA CA3124316A patent/CA3124316C/en active Active
- 2019-12-18 WO PCT/EP2019/086124 patent/WO2020127606A1/en not_active Ceased
- 2019-12-18 EP EP19828724.5A patent/EP3897610B1/en active Active
- 2019-12-18 AU AU2019410060A patent/AU2019410060A1/en not_active Abandoned
- 2019-12-18 ES ES19828724T patent/ES3026709T3/es active Active
-
2021
- 2021-06-18 CL CL2021001638A patent/CL2021001638A1/es unknown
- 2021-06-18 MX MX2025008270A patent/MX2025008270A/es unknown
- 2021-06-20 IL IL284213A patent/IL284213A/en unknown
-
2022
- 2022-06-06 US US17/833,745 patent/US11571408B2/en active Active
-
2023
- 2023-05-01 JP JP2023075517A patent/JP2023102787A/ja active Pending
- 2023-07-14 AU AU2023204682A patent/AU2023204682A1/en not_active Abandoned
-
2025
- 2025-02-28 US US19/066,854 patent/US20250312305A1/en active Pending
- 2025-03-24 JP JP2025049089A patent/JP2025094189A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023102787A5 (enExample) | ||
| JP2022009090A5 (enExample) | ||
| EP1778215B1 (en) | Anticancer effect enhancer | |
| JP2021098728A5 (enExample) | ||
| JP2023102786A5 (enExample) | ||
| RU2012106620A (ru) | Комбинации и способы введения терапевтических средств и комбинированной терапии | |
| JP2019503365A5 (enExample) | ||
| CN104955452B (zh) | 含有亚铁氨基酸螯合物的组合物在制备抗癌症的药物中的用途 | |
| US10702494B2 (en) | Method for cancer treatment | |
| Tewes et al. | Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study | |
| RU2010109359A (ru) | Азитромицин для лечения кожных заболеваний | |
| ES2414617T3 (es) | Ácidos grasos de cadena de longitud media, sales y triglicéridos en combinación con gemcitabina para el tratamiento del cáncer pancreático | |
| JP2023102787A (ja) | 癌の治療におけるドセタキセルの長期使用 | |
| US20110250292A1 (en) | Composition for improving radiotherapy for cancer | |
| CN101357134A (zh) | 抗肿瘤效果增强剂和抗肿瘤剂 | |
| CN101062041B (zh) | 葫芦素新的医药用途 | |
| US20220313652A1 (en) | Use of compound or pharmaceutically acceptable salt, dimer or trimer thereof in manufacture of medicament for treating cancer | |
| WO2021023291A1 (zh) | 原黄素在肺癌治疗中的应用 | |
| CN113713110B (zh) | 一种药物组合物及其应用 | |
| CN114259566B (zh) | 一种基于破坏氧化还原平衡的抗肿瘤组合物及应用 | |
| ES2393398T3 (es) | Agente reforzante del efecto antitumoral, agente antitumoral y procedimiento de terapia para el cáncer | |
| WO2021262749A1 (en) | Compositions and methods for preventing and/or treating viral infection | |
| JPWO2022094464A5 (enExample) | ||
| JP2008540566A (ja) | ２−デオキシグルコースを用いたがんの処置 | |
| CN119033797B (zh) | 抗肿瘤组合物及其应用 |